The low expression of the PU.1 transcription factor may contribute to mediate TRAIL resistance in AML cells through a lack of inhibitory effect on NF-kB-mediated up-regulation of anti-apoptotic genes such as c-FLIP, MCL-1, BCL-2 and BCL-XL upon TRAIL treatment [297]. Here, BCL2 is linked to acute myeloid leukemia.